Cargando…

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison

We tested the hypothesis that long-term treatment with pomaglumetad methionil would demonstrate significantly less weight gain than aripiprazole in patients with schizophrenia. In this 24-week, multicenter, randomized, double-blind, Phase 3 study, 678 schizophrenia patients were randomized to either...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, David H., Zhang, Lu, Millen, Brian A., Kinon, Bruce J., Gomez, Juan-Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977437/
https://www.ncbi.nlm.nih.gov/pubmed/24772351
http://dx.doi.org/10.1155/2014/758212
_version_ 1782310418415353856
author Adams, David H.
Zhang, Lu
Millen, Brian A.
Kinon, Bruce J.
Gomez, Juan-Carlos
author_facet Adams, David H.
Zhang, Lu
Millen, Brian A.
Kinon, Bruce J.
Gomez, Juan-Carlos
author_sort Adams, David H.
collection PubMed
description We tested the hypothesis that long-term treatment with pomaglumetad methionil would demonstrate significantly less weight gain than aripiprazole in patients with schizophrenia. In this 24-week, multicenter, randomized, double-blind, Phase 3 study, 678 schizophrenia patients were randomized to either pomaglumetad methionil (n = 516) or aripiprazole (n = 162). Treatment groups were also compared on efficacy and various safety measures, including serious adverse events (SAEs), discontinuation due to adverse events (AEs), treatment-emergent adverse events (TEAEs), extrapyramidal symptoms (EPS), and suicide-related thoughts and behaviors. The pomaglumetad methionil group showed significantly greater weight loss at Week 24 (Visit 12) compared with the aripiprazole group (−2.8 ± 0.4 versus 0.4 ± 0.6; P < 0.001). However, change in Positive and Negative Syndrome Scale (PANSS) total scores for aripiprazole was significantly greater than for pomaglumetad methionil (−15.58 ± 1.58 versus −12.03 ± 0.99; P = 0.045). The incidences of SAEs (8.2% versus 3.1%; P = 0.032) and discontinuation due to AEs (16.2% versus 8.7%; P = 0.020) were significantly higher for pomaglumetad methionil compared with aripiprazole. No statistically significant differences in the incidence of TEAEs, EPS, or suicidal ideation or behavior were noted between treatment groups. In conclusion, long-term treatment with pomaglumetad methionil resulted in significantly less weight gain than aripiprazole. This trial is registered with ClinicalTrials.gov NCT01328093.
format Online
Article
Text
id pubmed-3977437
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39774372014-04-27 Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison Adams, David H. Zhang, Lu Millen, Brian A. Kinon, Bruce J. Gomez, Juan-Carlos Schizophr Res Treatment Clinical Study We tested the hypothesis that long-term treatment with pomaglumetad methionil would demonstrate significantly less weight gain than aripiprazole in patients with schizophrenia. In this 24-week, multicenter, randomized, double-blind, Phase 3 study, 678 schizophrenia patients were randomized to either pomaglumetad methionil (n = 516) or aripiprazole (n = 162). Treatment groups were also compared on efficacy and various safety measures, including serious adverse events (SAEs), discontinuation due to adverse events (AEs), treatment-emergent adverse events (TEAEs), extrapyramidal symptoms (EPS), and suicide-related thoughts and behaviors. The pomaglumetad methionil group showed significantly greater weight loss at Week 24 (Visit 12) compared with the aripiprazole group (−2.8 ± 0.4 versus 0.4 ± 0.6; P < 0.001). However, change in Positive and Negative Syndrome Scale (PANSS) total scores for aripiprazole was significantly greater than for pomaglumetad methionil (−15.58 ± 1.58 versus −12.03 ± 0.99; P = 0.045). The incidences of SAEs (8.2% versus 3.1%; P = 0.032) and discontinuation due to AEs (16.2% versus 8.7%; P = 0.020) were significantly higher for pomaglumetad methionil compared with aripiprazole. No statistically significant differences in the incidence of TEAEs, EPS, or suicidal ideation or behavior were noted between treatment groups. In conclusion, long-term treatment with pomaglumetad methionil resulted in significantly less weight gain than aripiprazole. This trial is registered with ClinicalTrials.gov NCT01328093. Hindawi Publishing Corporation 2014 2014-03-19 /pmc/articles/PMC3977437/ /pubmed/24772351 http://dx.doi.org/10.1155/2014/758212 Text en Copyright © 2014 David H. Adams et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Adams, David H.
Zhang, Lu
Millen, Brian A.
Kinon, Bruce J.
Gomez, Juan-Carlos
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
title Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
title_full Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
title_fullStr Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
title_full_unstemmed Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
title_short Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
title_sort pomaglumetad methionil (ly2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977437/
https://www.ncbi.nlm.nih.gov/pubmed/24772351
http://dx.doi.org/10.1155/2014/758212
work_keys_str_mv AT adamsdavidh pomaglumetadmethionilly2140023monohydrateandaripiprazoleinpatientswithschizophreniaaphase3multicenterdoubleblindcomparison
AT zhanglu pomaglumetadmethionilly2140023monohydrateandaripiprazoleinpatientswithschizophreniaaphase3multicenterdoubleblindcomparison
AT millenbriana pomaglumetadmethionilly2140023monohydrateandaripiprazoleinpatientswithschizophreniaaphase3multicenterdoubleblindcomparison
AT kinonbrucej pomaglumetadmethionilly2140023monohydrateandaripiprazoleinpatientswithschizophreniaaphase3multicenterdoubleblindcomparison
AT gomezjuancarlos pomaglumetadmethionilly2140023monohydrateandaripiprazoleinpatientswithschizophreniaaphase3multicenterdoubleblindcomparison